Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › glycopyrronium

glycopyrronium

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of glycopyrronium

19 trials tracked of glycopyrronium: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 374 citations.

19Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 10 Phase 3 4 Phase 2 1 Other / NA 4
  1. Phase 3 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed · 374 cited
  2. Phase 4 Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen Completed · 54 cited
  3. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 12 cited
  4. Phase 4 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery Completed
  5. Phase 4 Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD Completed
  6. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
Show 13 more trials
  1. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  2. Phase 4 Dexmedetomidine and Propofol for Pediatric MRI Sedation Completed
  3. Phase 4 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy Completed
  4. Phase 4 Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block Completed
  5. Phase 4 A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed
  6. Phase 3 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) Completed
  7. Phase 3 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) Completed
  8. Phase 3 A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo Completed
  9. Phase 2 Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Completed
  10. N/A Intraoperative Video Laryngoscopy as Adjunct for Nerve Monitoring Completed
  11. N/A Decision Support for Intraoperative Low Blood Pressure Completed
  12. N/A Chronotropic Incompetence in Patients With HFpEF Completed
  13. N/A Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) for COPD Maintenance
Pulmonology & Critical Care FDA Approval
FDA Approves Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) for COPD Maintenance FDA approves new triple-combination inhaler Breztri Aerosphere for COPD.
The FDA approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for maintenance treatment of COPD. It is a triple-combin…
The FDA approved Breztri Aerosphere, a triple-combination inhaler, for the long-term treatment of chronic obstructive pulmonary disease (COP…
FDA May 2, 2026
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma
Allergy & Immunology RCT
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma New Asthma Drug Cuts Attacks Without Recent Crisis
This phase 3 randomised, double-blind, double-dummy, parallel-group trial evaluated budesonide-glycopyrronium-formoterol fumarate dihydrate …
A new asthma combo therapy improves breathing and lowers severe flare-up risk for patients who haven't had a recent emergency room visit.
Apr 14, 2026